Protein is an important component of all organisms. Each protein molecule consists of one or more polypeptide chains made of amino acids. There are 20 naturally occurring amino acids. Different series of amino acids are linked together by peptide bonds to form protein chains. Each protein has a unique sequence of amino acids. All the functions of proteins are dependent on their structures. Although information necessary for life is encoded by DNA or RNA, proteins perform a wide range of biological functions within organisms, including enzyme catalysis, defense, transport, support, motion, and regulation. According to their functions in the body, proteins can be divided into different categories, such as antibody, enzyme, messenger, structural component, and transport/ storage protein. Given the important functions of proteins, proteins have been studied intensively and applied widely.
In the past, the major way to obtain a specific protein was to isolate it from a natural source, which is generally inefficient and time-consuming. Recent advances in recombinant molecule biological techniques have made it possible to clone the DNA encoding a specific protein into an expression vector and express the protein in expression systems, such as bacteria, yeast, insect cells, and mammalian cells. Simply put, recombinant proteins are translated products of exogenous DNA in living cells. The production of recombinant proteins generally contains two major steps: molecule cloning and protein expression. Currently, recombinant protein production is one of the most powerful techniques used in life sciences. Recombinant proteins have wide applications in medicine, research, and biotechnology.
Therapeutic proteins provide important therapies for a variety of diseases, such as diabetes, cancer, infectious diseases, hemophilia, and anemia. Common therapeutic proteins include antibodies, FC fusion proteins, hormones, interleukins, enzymes, and anticoagulants. There is a growing demand for recombinant proteins for therapeutic applications. Human proteins obtained through genetic engineering play a key role in therapeutic medicines market. Currently, most of all recombinant therapeutic proteins are produced in mammalian cells because mammalian cells are capable of producing high-quality proteins similar to the naturally occurring ones. In addition, many approved recombinant therapeutic proteins are generated in Escherichia coli due to its well-characterized genetics, rapid growth, and high-yield production.
Basically, therapeutic proteins can be classified into four groups.
Group I: Therapeutic proteins with enzymatic or regulatory activity. These proteins replace a protein that is deficient or abnormal, up-regulate an existing pathway, or provide a new function or activity.
Group II: Therapeutic proteins with special targeting activity. These proteins interfere with a molecule or organism or deliver other molecules.
Group III: Therapeutic proteins as vaccines. These proteins help protect against foreign agents, autoimmune diseases, and cancer.
Group IV: Therapeutic proteins as diagnostics. These proteins are generally purified and recombinant proteins.
Recombinant proteins help to elucidate the basic and fundamental principles of an organism. These molecules can be used to identify and locate the position of the protein encoded by a specific gene, and to uncover the function of other genes in various cellular activities such as cell signaling, metabolism, growth, replication and death, transcription, translation, and protein modification. Thus, recombinant proteins are frequently used in molecular biology, cell biology, biochemistry, structural and biophysical studies, and many other research fields.
Recombinant proteins are useful tools in understanding protein-protein interactions. They have proven performance in several laboratory techniques, such as ELISA, Western Blot, and immunohistochemistry (IHC). Recombinant proteins can be used to develop enzymatic assays. When used in conjunction with a matched antibody pair, recombinant proteins can be used as standards such as ELISA standards. Moreover, recombinant proteins can be used as positive controls in Western blots.
Recombinant proteins are also used in industry, food production, agriculture, and bioengineering. For example, in breeding industry, enzymes can be added to animal feed to increase the nutritional value of feed ingredients, reduce feed and waste management costs, support animal gut health, enhance animal performance and improve the environment. Besides, lactic acid bacteria (LAB) have been used for a long time for the production of fermented foods, and recently, LAB has been engineered for the expression of recombinant proteins, which would have wide applications such as improving human/animal digestion and nutrition.
However, recombinant proteins also have limitations.
1. In some cases, the production of recombinant proteins is complex, expensive, and time-consuming.
2. The recombinant proteins produced in cells may not be the same as the natural forms. This difference may reduce the effectiveness of therapeutic recombinant proteins and even cause side effects. Additionally, this difference may affect the results of experiments.
3. A major concern for all recombinant drugs is immunogenicity. All biotechnologically produced therapeutics may exhibit some form of immunogenicity. It is difficult to predict the safety of novel therapeutic proteins.
Overall, advancements in the field of biotechnology have increased and facilitated the production of recombinant proteins for various applications. Although recombinant proteins still have some drawbacks, they are important in medicine, research, and biotechnology.
4. The Latest Researches of Recombinant Proteins
Here, we numerate several researches of recombinant proteins from various fields.
4.1 Recombinant proteins and disease
1. The Georgetown University-led study, published in Scientific Reports, reported that forced expression of the protein FGFBP3 (BP3 for short) in a laboratory strain of obese mice showed a remarkable reduction of their fat mass despite a genetic predisposition to eat all the time. The results of this study suggest that the protein FGFBP3 might offer novel therapy to reverse disorders associated with metabolic syndrome, such as type 2 diabetes and fatty liver disease. But, because BP3 is a natural protein and not an artificial drug, clinical trials of recombinant human BP3 could begin after a final round of preclinical studies. Please click here to obtain more information.
2. PD-L2, one of the key players in immune checkpoint therapy, is the focus of the 2018 Nobel Prize for Physiology & Medicine. This work pioneered by Professor James P Allison from the USA and Professor Tasuku Honjo from Japan, has led to treatments for cancers, such as melanoma, lung cancer and others based upon immune checkpoint therapy. Recently, AMSBIO has added an important new product to its immunotherapy range - a PD-L2 / TCR activator - CHO Recombinant Cell Line. Please click here to view more information.
3. In proof-of-concept experiments, University of Alabama at Birmingham researchers, led by X. Long Zheng, M.D., Ph.D., Robert B. Adams Professor and Division Director of Laboratory Medicine in the Department of Pathology in UAB's School of Medicine, have highlighted a potential therapy for a rare but potentially deadly blood-clotting disorder, TTP. The results of this study for the first time demonstrate that transfusion of rADAMTS13-loaded platelets may be a novel and potentially effective therapeutic approach for arterial thrombosis, associated with congenital and immune-mediated TTP. Please click here to obtain more information.
4.2 Recombinant proteins and vaccine
1. A new vaccine strategy, also known as using a specialist recombinant virus vaccine, could offer protection to millions of chickens threatened by a serious respiratory disease, reported by researchers at the University of Edinburgh and the Pirbright Institute. These vaccines use harmless or weak versions of a virus or bacteria to introduce microbes into cells in the body. In this instance, experts used recombinant viruses with different spike proteins as vaccines to build two versions of a harmless virus. Please click here to view more information.
2. According to new research published in Nature Communications, a novel vaccine, also called LASSARAB, designed to protect people from both Lassa fever and rabies showed promise in preclinical testing. The inactivated recombinant vaccine candidate uses a weakened rabies virus vector, or carrier. The research team inserted genetic material from Lassa virus into the rabies virus vector so the vaccine expresses surface proteins from both the Lassa virus and the rabies virus. These surface proteins prompt an immune response against both Lassa and rabies viruses. The recombinant vaccine was then inactivated to "kill" the live rabies virus used to make the carrier. Please click here to view more information.